A innovation grant received from CTI to develop Rimeporide

EspeRare and University of Geneva have received a 235’000 CHF grant from the Swiss Commission for Technology and Innovation (CTI).

This contribution is supporting the development of Rimeporide, a drug that would have the potiential to treat Duchenne Muscular Dystorphy, a neuromuscular pediatric disease for which no cure exists. This grant from the the Swiss Commission for Technology and Innovation is financing EspeRare's preclinical investigation of Rimeporide in collaboration with the Geneva University School of Pharmacy. Within the University, the research on Rimeporide is conducted by Professor Leonardo Scapozza’s group under the supervision of Dr Olivier Dorchies, an international expert in Duchenne preclinical investigation.

About the CTI: As the Confederation's innovation promotion agency, the Swiss Commission for Technology and Innovation (CTI) lends support to R&D projects, to entrepreneurship as well as to the development of start-up companies in Switzerland. CTI helps to optimise knowledge and technology transfer through the use of national thematic networks.
Click here for further information